Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors
Journal of Medicinal Chemistry · 23.02.2023 · 66 (4) · 2386-2395
DOI: 10.1021/acs.jmedchem.2c00851 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 02.02.2023. Verfasst von Andreas Blum und 12 weiteren Autor:innen. Beteiligte Einrichtung: Merck Healthcare KGaA, Frankfurter Str. 250, 64293Darmstadt, Germany. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Antineoplastic Agents, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
The treatment of gastrointestinal stromal tumors (GISTs) driven by activating mutations in the KIT gene is a prime example of targeted therapy for treatment of cancer. The approval of the tyrosine kinase inhibitor imatinib has significantly improved patient survival, but emerging resistance under treatment and relapse is observed. Several additional KIT inhibitors have been approved; still, there is a high unmet need for KIT inhibitors with high selectivity and broad coverage of all clinically relevant KIT mutants. An imidazopyridine hit featuring excellent kinase selectivity was identified in a high-throughput screen (HTS) and optimized to the clinical candidate M4205 (IDRX-42). This molecule has a superior profile compared to approved drugs, suggesting a best-in-class potential for recurrent and metastatic GISTs driven by KIT mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Merck Healthcare KGaA, Frankfurter Str. 250, 64293Darmstadt, Germany.
ORCID-Profile: Andreas Blum, Hans-Peter Buchstaller
Zitieren
APA
Blum, A., Dorsch, D., Linde, N., Brandstetter, S., Buchstaller, H. P., Busch, M., Glaser, N., Grädler, U., Ruff, A., Petersson, C., Schieferstein, H., Sherbetjian, E., & Esdar, C. (2023). Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors. Journal of Medicinal Chemistry, 66(4), 2386-2395. https://doi.org/10.1021/acs.jmedchem.2c00851
Vancouver
Blum A, Dorsch D, Linde N, Brandstetter S, Buchstaller HP, Busch M, et al. Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors. Journal of Medicinal Chemistry. 2023;66(4):2386-2395. doi:10.1021/acs.jmedchem.2c00851
BibTeX
@article{Blum2023,
author = {Blum, Andreas and Dorsch, Dieter and Linde, Nina and Brandstetter, Susanne and Buchstaller, Hans-Peter and Busch, Michael and Glaser, Nina and Grädler, Ulrich and Ruff, Aaron and Petersson, Carl and Schieferstein, Hanno and Sherbetjian, Eva and Esdar, Christina},
title = {Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {4},
pages = {2386--2395},
doi = {10.1021/acs.jmedchem.2c00851}
}
EUVIMED